Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 19/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29914234 | 1.00 | TNIK (0.64) | TNIKCDK1CDK2 | |
| SCHEMBL29914229 | 0.86 | TNIK (0.62) | TNIK | |
| SCHEMBL21259093 | 0.86 | TNIK (0.62) | TNIK | |
| SCHEMBL21259101 | 0.82 | TNIK (0.70) | TNIKCDK1CDK2 | |
| SCHEMBL29914233 | 0.82 | TNIK (0.70) | TNIKCDK1CDK2 | |
| SCHEMBL21259146 | 0.80 | TNIK (0.62) | TNIKCDK1CDK2 | |
| SCHEMBL29914225 | 0.80 | TNIK (0.62) | TNIKCDK1CDK2 | |
| SCHEMBL21248484 | 0.78 | TNIK (1.00) | TNIK | |
| SCHEMBL29965738 | 0.78 | TNIK (1.00) | TNIK | |
| SCHEMBL21247606 | 0.78 | TNIK (1.00) | TNIKCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749647-B1 | N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-09-27 | — | — | EP | disclosed |
| EP-3749647-B1 | N-(5-(PHENYL)-1H-PYRAZOL-3-YL)-1H-INDOL-5-AMINE DERIVATIVES AS TNIK INHIBITORS FOR THE TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-09-27 | — | — | EP | disclosed |
| US-20210047300-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-02-18 | — | — | US | disclosed |
| US-20210047300-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-02-18 | — | — | US | disclosed |
| WO-2019156438-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047300-A1 | HETERO RING-FUSED PHENYL COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF | TNNI3K, TNK1, TNIK | TNIK 3/4885CDK1 1722/4885CDK2 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.